Tumor Lysis Syndrome and the Feasibility of an All-Oral Regimen

Dr Shadman addresses tumor lysis syndrome, a longstanding concern with BCL2 inhibition, in light of the absence of any tumor lysis syndrome events in this study. He frames two considerations. First, avoiding laboratory and clinical tumor lysis events remains essential, supporting the standard initial debulking and gradual ramp-up dosing strategies used for safety. Second, he cautions against overly conservative management, noting that with debulking many patients are not at meaningful risk, and that excessively strict protocols can lead to underutilization of an important class; he observes that BCL2 inhibition has historically been underused. Dr Shadman highlights that the sonrotoclax program is exploring ramp-up strategies and risk stratification, applying strict measures when warranted but remaining clinically reasonable when they are not. He views this effort to make the regimen more user-friendly for lower-risk patients as a distinctive strength that could increase utilization and support an all-oral, potentially community-deliverable approach for chronic lymphocytic leukemia.